| answer text |
<p>NHS England has been in intensive discussions with Vertex to encourage it to price
Orkambi at a level that would allow NHS England to fund its use without adversely
impacting other patients. I and the Parliamentary Under-Secretary of State for Health
(Lord O’Shaughnessy) have been keeping an extremely close eye on these discussions
and wrote to Vertex in April, urging it to commit to pricing that is responsible and
proportionate. I also re-iterated this message in the adjournment debate on 17 July,
Official report, columns 383-4.</p>
|
 |
